Hydrocortisone modified-release hard capsules (Efmody®). HTA ID: 21042

Assessment Status Assessment process complete
HTA ID 21042
Drug Hydrocortisone modified-release hard capsules
Brand Efmody®
Indication For the treatment of congenital adrenal hyperplasia in adolescents aged 12 years and over and adults.
Assessment Process
Rapid review commissioned 08/09/2021
Rapid review completed 04/11/2021
Rapid review outcome A full HTA is not recommended. The NCPE recommends that Efmody® not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.